Abstract: In certain aspects, the present invention provides novel ActRIIB variants (in a homomultimeric or heteromultimeric form), as well as compositions and methods for using those variants to treat an indication associated with undesired activity of one or more TGF?-superfamily ligands. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

Abstract: “UNDULATING TRACK AND MECHANISMS FOR FORMATION OF THE WAVES ON THIS TRACK”, describes apparatus that can be used with recreational purposes, sports, industrial, among other applications, comprising a rolling track or raceway (1), consisting of flexible material mounted on a compatible structure, also flexible, track-type tubes (2) being supported by the ends of the conveyor pipe (2) in lateral supports (3) of the beam type or the wall or similar structure; and to contain a cart (4) with wheels (41) supported on rails (5) mounted underneath the bearing race (1) and having a wave forming mechanism, random or controlled, mounted on said cart (4) moving said wave-forming mechanism along the bearing track (1) by means of a traction mechanism of the type carried by chains or steel cables.

Abstract: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.

Abstract: The invention relates to pharmaceutical compositions comprising anhydrous(2R,3S)4-acetoxy-2-a-benzoyloxy-5?-20-epoxy-1,7-?-10-?-tri-hydroxy-9-oxo-tax-11-en-13?-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I)(docetaxel) and 4-acetoxy-2-?-benzoyloxy-5-?-20-epoxy-1,7?-10-?-tri-hydroxy-9-oxo-tax-11-en-13?-il (2R,3S)3-benzoylamino-2-hydroxy-3-phenylpropionate (II) (paclitaxel), methods for treating neoplastic tumors using anhydrous docetaxel and paclitaxel, and a process for the preparation of the anhydrous docetaxel and paclitaxel.

Abstract: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.

Abstract: Embodiments of the present invention relate to a non-aqueous antifungal composition that comprises an alcoholic solvent, a preservative, a wetting agent and a flavoring agent, which can be used in the bakery industry when applied on the surface of products by spraying. Embodiments of the present invention result in food products having result reduced contamination by fungi and increased shelf life, without adversely affecting the product's flavor profile, texture and appearance.

Abstract: The present invention relates to a method for the determination of the total acid number and naphthenic acid number of petroleum, petroleum cuts and petroleum emulsions of water-in-oil type by mid-infrared spectroscopy utilising correlation between data gathered by means of absorption spectrums obtained with a Fourier-transform infrared spectrophotometer operating in the mid-infrared band equipped with an attenuated total reflectance (ATR) accessory, and acidity results obtained through reference methods utilising a multivariate regression model.

Abstract: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. Piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.

Abstract: This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable injectable solutions, and their use, more specifically, APIs which are taxane derivatives, especially (2R,3S) 4-acetoxy-2-?-benzoyloxy-5?-20-epoxy-1,7-?-10-?-tri-hydroxy-9-oxo-tax-11-en-13?-il 3-tert-butoxy carbonylamino-2-hydroxy-3-phenylpropionate (I); 4-acetoxy-2-?-benzoyloxy-5-?-20-epoxy-1,7?-10-?-tri-hidroxy-9-oxo-tax-11-en-13?-il (2R,3S) 3-benzoylamino-2-hydroxy-3-phenylpropionate (II), and particularly 4-acetoxy-2-?-benzoyloxy-5?-20-epoxy-1, 7-?-10-?-tri-hidroxy-9-oxo-tax-11-en-13?-il (2R,3S) 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate tri-hydrate (III).

Abstract: The present invention relates to a method for the determination of the total acid number and naphthenic acid number of petroleum, petroleum cuts and petroleum emulsions of water-in-oil type by mid-infrared spectroscopy utilising correlation between data gathered by means of absorption spectrums obtained with a Fourier-transform infrared spectrophotometer operating in the mid-infrared band equipped with an attenuated total reflectance (ATR) accessory, and acidity results obtained through reference methods utilising a multivariate regression model.